Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026

Standard first-line treatment for diffuse large B-cell lymphoma (DLBCL) is R-CHOP, a regimen comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. While effective for many, approximately 30-40% of patients experience treatment failure, necessitating further therapeutic strategies.¹ This outcome underscores the ongoing clinical imperative to identify and integrate novel agents that can enhance the depth and durability of response in the frontline setting, thereby improving long-term survival for a broader patient population.² DLBCL is the most common aggressive non-Hodgkin lymphoma, accounting for approximately 30-40% of all adult non-Hodgkin lymphomas. Its incidence increases with age, with a median age at diagnosis in the mid-60s. The disease is characterized by significant clinical and biological heterogeneity, which contributes to the variable responses observed with standard therapies. The development of new therapeutic approaches is crucial for patients who do not achieve durable remission with R-CHOP, as their prognosis remains poor. Tafasitamab is a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody that works by inducing direct tumor cell lysis and enhancing antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

The trial

A multicenter, randomized, open-label, phase 3 study, presented at ASCO 2026, investigated the efficacy and safety of tafasitamab in combination with R-CHOP (T-R-CHOP) compared to R-CHOP alone in adult patients with newly diagnosed DLBCL.³ The trial enrolled 880 patients across 110 sites globally, randomized 1:1 to receive either T-R-CHOP or R-CHOP. Patients were required to have previously untreated, CD20-positive DLBCL, an ECOG performance status of 0-2, and adequate organ function.³ Exclusion criteria included prior systemic therapy for DLBCL, central nervous system lymphoma, or a history of other malignancies requiring active treatment. Patients with significant cardiovascular disease or uncontrolled infections were also excluded to ensure patient safety and minimize confounding factors. Tafasitamab was administered intravenously at 12 mg/kg on days 1, 8, 15, and 22 of cycle 1, and on days 1 and 15 of subsequent cycles, in conjunction with standard R-CHOP for 6-8 cycles. The primary endpoint was progression-free survival (PFS), assessed by an independent review committee. Key secondary endpoints included overall survival (OS), complete response (CR) rate, duration of response (DOR), and safety.³

The median follow-up for the study was 36.5 months. The T-R-CHOP arm demonstrated a statistically significant improvement in PFS compared to the R-CHOP arm. The hazard ratio (HR) for PFS was 0.68 (95% CI, 0.54-0.85; p=0.003), indicating a 32% reduction in the risk of progression or death with the addition of tafasitamab.³ The median PFS was not reached in the T-R-CHOP arm versus 48.2 months in the R-CHOP arm. The 3-year PFS rate was 72.1% in the T-R-CHOP group compared to 61.5% in the R-CHOP group.³

Regarding secondary endpoints, the complete response rate was numerically higher in the T-R-CHOP arm at 82.5% versus 75.9% in the R-CHOP arm (p=0.041).³ Overall survival data are still maturing, but a positive trend favoring T-R-CHOP was observed, with an HR of 0.75 (95% CI, 0.58-0.97; p=0.028).³ The safety profile of T-R-CHOP was consistent with the known safety profiles of its individual components. The most common grade 3 or higher adverse events in the T-R-CHOP arm included neutropenia (38% vs. 32% in R-CHOP), thrombocytopenia (12% vs. 9%), and febrile neutropenia (8% vs. 6%). Infusion-related reactions specific to tafasitamab were generally low grade and manageable. Discontinuation rates due to adverse events were comparable between the two arms.³

The study's limitations include the open-label design, which could introduce bias, although objective endpoints like PFS were assessed by an independent committee. Longer follow-up is required to fully ascertain the overall survival benefit and the long-term safety profile of T-R-CHOP. While the current follow-up period provides robust PFS data, the full impact on OS, particularly in a disease with a long natural history for some patients, requires extended observation. The generalizability of these results may also be influenced by the specific patient population enrolled, which included patients with an ECOG performance status of 0-2 and adequate organ function, potentially excluding sicker patients who might also benefit from enhanced frontline therapy. Future research should also explore the utility of T-R-CHOP in specific high-risk subgroups of DLBCL patients, such as those with double-hit or triple-hit lymphoma, where current R-CHOP outcomes are particularly poor.⁴ Further investigation into biomarkers that predict response to tafasitamab would also be beneficial for patient selection.